Deakin University
Browse

Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pis) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II! clinical trial

conference contribution
posted on 2022-11-25, 03:55 authored by Mustafa Khasraw, Sally Anne McCowatt, Marc E Buyse, Zoltan Kerstes, Michael Back, Ganessan Kichenadasse, Helen Wheeler
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pis) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II! clinical trial

History

Volume

32

Location

Chicago, IL

Publisher DOI

Start date

2014-05-30

End date

2014-06-03

ISSN

0732-183X

eISSN

1527-7755

Language

English

Author URL

Publication classification

E3.1 Extract of paper

Title of proceedings

JOURNAL OF CLINICAL ONCOLOGY

Event

50th Annual Meeting of the American-Society-of-Clinical-Oncology

Issue

15

Publisher

AMER SOC CLINICAL ONCOLOGY

Usage metrics

    Research Publications

    Categories

    Keywords

    Science & TechnologyLife Sciences & BiomedicineOncology

    Licence

    All Rights Reserved

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC